December 22, 2014 10:56 AM ET

Pharmaceuticals

Company Overview of Cognition Therapeutics, Inc.

Company Overview

Cognition Therapeutics, Inc., a drug discovery company, develops small molecule therapeutics for Alzheimer's and other neurodegenerative diseases. Its products targets the toxic proteins that cause the cognitive decline associated with Alzheimer's disease and other degenerative diseases of the human brain. The company was incorporated in 2007 and is based in Pittsburgh, Pennsylvania.

2403 Sidney Street

Suite 261

Pittsburgh, PA 15203

United States

Founded in 2007

Phone:

412-481-2210

Fax:

412-481-2216

Key Executives for Cognition Therapeutics, Inc.

Chief Executive Officer and President
Age: 49
Chief Medicinal Chemistry Advisor
Scientific Advisor
Scientific Advisor
Scientific Advisor
Compensation as of Fiscal Year 2014.

Cognition Therapeutics, Inc. Key Developments

Cognition Therapeutics Inc. Announces Publication of Research Identifying Sigma-2/PGRMC1 Receptor as Major New Drug Target for Alzheimer's Disease Therapy

Cognition Therapeutics Inc. announced the publication online of two articles entitled: Alzheimer's therapeutics targeting Amyloid beta 1-42 oligomers I: Abeta oligomers binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits and Alzheimers therapeutics targeting Amyloid beta 1-42 oligomers II: sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity, in PLOS ONE, the peer-reviewed open access science and medicine journal. Together these articles describe the coincident discovery of a major new drug target in the human brain implicated in Alzheimer's disease and a series of investigational drug candidates, which potentially can halt and reverse the insidious and devastating memory loss that Alzheimer's brings. Sigma-2/PGRMC1 receptor, the new Alzheimer's drug target, mediates the pathological effects of the water-soluble oligomeric version of amyloid beta 1-42 protein (Abeta), the agent widely thought to be a major causative factor of Alzheimer's disease. The first article in PLOS, entitled Alzheimer's therapeutics targeting Amyloid beta 1-42 oligomers I: Abeta oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits, describes company's Alzheimer's screening platform and proprietary CNS-biased compound library and its discovery of a set of candidate agents that are capable of blocking the toxic effects of both synthetic and human Abeta oligomers on processes important to neuronal cell communication and viability and ultimately memory formation and consolidation. The company's compounds prevent Abeta-induced neuronal degeneration in a mouse brain cell culture system and reverse Abeta-induced memory deficits in preclinical rodent models of memory and learning using both normal and APP-Swedish London transgenic mice. In the second article, entitled Alzheimers therapeutics targeting Amyloid beta 1-42 oligomers II: sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity, the company screened its compounds in industry-standard counterscreening assays to determine which receptors the compounds bound to. Sigma-2/PGRMC1 receptor protein was the only receptor that the compounds bound to with significant affinity, and further studies suggested it to be a major pharmacologically tractable target for Abeta toxicity in human brain. Sigma-2/PGRMC1 plays an important role in controlling whether or not certain proteins that are required for normal memory formation are located on the surface of brain cells. When Abeta builds up in the brain, as can be seen in older humans or Down's syndrome individuals, it forms oligomers that stick to the brain cell synapses and result in the reduction of proteins that are required for normal memory formation. The findings reported here make an important link between these two observations, and suggest that oligomer interactions with sigma-2/PGRMC1 may lead directly to this reduction.

Similar Private Companies By Industry

Company Name Region
LarreaRX Inc. United States
Upstate Pharma, LLC United States
Diasome Pharmaceuticals, Inc. United States
Sanofi US Services Inc. United States
Amenni, LLC United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
March 20, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Cognition Therapeutics, Inc., please visit www.cogrx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.